$21.15+4.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $3M | $9.6M | -69.29% |
| Profit | -$20.3M | -$9.2M | -120.27% |
| Profit per share | -$0.93 | -$0.72 | -29.17% |
| Free Cash Flow | -$17.3M | -$15.2M | -13.90% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
GS-1179, formerly ABI-1179, is an investigational helicase-primase inhibitor being developed for HSV infections. It was advanced through early clinical stage development under Assembly Bio’s collaboration with Gilead. HSV helicase-primase inhibitors target an enzyme complex essential for viral replication and represent a mechanism distinct from currently available nucleoside analog therapies. GS-1179 was selected for advancement by Gilead in the HSV HPI program based on encouraging Phase 1b results and its potential to support once-weekly oral dosing.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Assembly Biosciences, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Assembly Biosciences, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Assembly Biosciences, Inc.'s results release of November 12, 2026; its quarterly report has since been filed.
Actual
$3M
-73% y/y
-78% q/q
Guided
—
No guide given
Actual
-$0.93
Guided
—
No guide given
Actual
-$23.4M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.